| Bioactivity | Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. Ac-MRGDH-NH2 can be used to synthesize the diastereoisomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic bis-aqua ruthenium warhead [Ru(Ph2phen)2(OH2)2]2+, and Ac-MRGDH-NH2 possesses integrin targeting ability and photosubstitution properties. Therefore, Ac-MRGDH-NH2 can be utilized in research on tumor-targeted photodynamic activation chemotherapy (PACT)[1]. |
| Sequence | Ac-Met-Arg-Gly-Asp-His-NH2 |
| Shortening | Ac-MRGDH-NH2 |
| Formula | C25H41N11O8S |
| Molar Mass | 655.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang L, et al. Cyclic ruthenium-peptide conjugates as integrin-targeting phototherapeutic prodrugs for the treatment of brain tumors[J]. Journal of the American Chemical Society, 2023, 145(27): 14963-14980. |